JNJ
stock47ConservativeJohnson & Johnson
Health Care
Snapshot
Diversified pharmaceuticals and medical-devices company. A defensive dividend aristocrat with broad, durable healthcare franchises.
Long-Term Total Return
Decade-scale view, dividends reinvested, vs. the S&P 500.
Growth of $10,000 invested at the start of the period, total return (price + reinvested dividends). Illustrative.
Risk Profile
Lower volatility, steadier — capital preservation and income.
2–5 Year Outlook
Hypothetical bear / base / bull scenarios — not a prediction.
Hypothetical 5-year scenarios for $10,000 invested today.
| Scenario | Annualized | Total return | $10,000 → |
|---|---|---|---|
| Bull 9%/yr FCF growth, exit 23× FCF | +12.3%/yr | +79% | $17,867 |
| Base 4%/yr FCF growth, exit 20× FCF | +4.6%/yr | +25% | $12,497 |
| Bear 0%/yr FCF growth, exit 13× FCF | -5.3%/yr | -24% | $7,600 |
Projects free cash flow forward and applies an exit valuation multiple (current ≈ 22× FCF). Dividends added at the current yield.
Technical Indicators
Objective price signals — moving averages, RSI, 52-week range — to interpret, not act on.
Illustrative daily prices (last ~9 months) with 50- and 200-day moving averages.
- Trading above its 50- and 200-day moving averages — a textbook uptrend.
- RSI 47 — neutral (neither overbought nor oversold).
- At or near its 52-week high.
- MACD is below its signal line (negative momentum).
Technical indicators are objective descriptions of price behavior, not signals to act on. They are computed from illustrative sample prices and say nothing about a company's value. Not investment advice.
Fundamental Trends
Ten-plus years of the figures that drive long-term value.
10-year fundamental trend charts
Track revenue, earnings, free cash flow, ROIC, share count, and dividends over a decade-plus — a Premium research tool.
$9/mo or $84/yr · cancel anytime
Valuation Context
Valuation context
See P/E, P/FCF, and EV/EBITDA against historical and sector medians with Premium.
$9/mo or $84/yr · cancel anytime
Moat Analysis
Patent-protected drugs, trusted consumer brands, and entrenched hospital relationships in devices provide durable, diversified advantages.
Pharma pipeline and medtech innovation sustain modest but reliable growth.
Risk Factors
What could impair the long-term thesis.
- Patent cliffs on key drugs
- Litigation overhangs
- Pricing/regulatory pressure
Hypothetical Growth
What a past investment would be worth today.
Hypothetical growth calculator
See what an investment made years ago would be worth today, vs. the S&P 500 — a Premium tool.
$9/mo or $84/yr · cancel anytime
Forward Scenario Modeler
Project a starting investment across multi-decade horizons.
Forward scenario modeler
Model conservative, base, and optimistic returns across 10–40 year horizons with Premium.
$9/mo or $84/yr · cancel anytime
Data as of 2025-12-31. Illustrative sample data for research & education — not live market data, and not a recommendation to buy or sell JNJ.